T a [ 行业研究|可选消费 证券研究报告 可选消费行业周报、月报 2025 年 07 月 22 日 b l [Table_Title] 泡泡玛特业绩预告亮眼，市监局约谈三 e _ M 大外卖平台 ——美护商社行业周报 [Table_Summary] 报告要点： 市场表现 ] 本周（2025.07.14-2025.07.18），商贸零售/社会服务/美容护理分别 +0.23%/+1.05%/-0.14%，在 31 个一级行业中排名第 18/13/22，同期 上证综指+0.69%，深证成指+2.04%，沪深 300+1.09%。 细分子板块来看，本周专业服务/教育/一般零售涨幅居前，分别 +3.25%/+1.21%/+0.86%。饰品/专业连锁/酒店餐饮跌幅居前，分别为 -2.60%/-1.39%/-1.18%。 本周行业重点事件及资讯 2025 年 1-6 月社会消费品零售总额 24.55 万亿，同比+5%。6 月社零 总额 4.23 万亿元，同比增长 4.8%，低于 wind 一致预期的 8.4%，受 端午错期及 618 需求释放前置影响，增速有所放缓。分消费类型来看， 6 月商品零售同比+5.3%，餐饮收 ...

Investment Rating - The report maintains a "Positive" outlook on the cosmetics and medical beauty industry, highlighting innovative business models driving growth in the light medical beauty sector, particularly recommending attention to the company "Xinyang" [2][9]. Core Insights - The cosmetics and medical beauty sector has underperformed the market recently, with the Shenwan Beauty Care Index declining by 0.1% from July 11 to July 18, 2025, while the Shenwan Cosmetics Index fell by 0.9%, underperforming the Shenwan A Index by 2.3 percentage points [3][4]. - Innovative business models are driving growth in light medical beauty, contrasting with traditional medical beauty institutions facing stagnation due to high costs and weak consumer demand. Xinyang's high cost-performance ratio, chain operations, and app-based customer conversion model are seen as new growth drivers for the sector [9][10]. - The report emphasizes the importance of supply-side innovations in stimulating consumer demand and driving industry recovery, despite short-term macroeconomic challenges [9]. Summary by Sections Industry Performance - The cosmetics and medical beauty sector has shown weak performance compared to the market, with specific indices reflecting declines during the reporting period [3][4]. - The top-performing stocks in the sector included Zhongshun Jierou (+10.8%) and Juzibio (+6.1%), while the worst performers were Shangmei Shares (-11.1%) and Baiya Shares (-4.3%) [5]. Key Company Insights - Linqingxuan, a high-end domestic skincare brand, has seen revenue growth from 690 million yuan in 2022 to 1.21 billion yuan in 2024, with net profit turning from a loss of 6 million yuan to a profit of 187 million yuan [10][15]. - The company has established a strong product matrix and supply chain advantages, with production capacity reaching 40 million units annually [16][17]. - The report also highlights the growth of the "Plant Doctor" brand, which has achieved a net profit CAGR of 24% from 2022 to 2024, supported by a robust channel network and operational efficiencies [10][12]. Market Trends - The report notes a shift in the cosmetics market from quantity to quality, with a significant increase in e-commerce sales, which accounted for 47% of total cosmetics sales in 2024, up from 22% in 2016 [11]. - The domestic market is witnessing a rise in local brands, with a notable increase in market share for domestic products, reflecting changing consumer preferences and the impact of the "national tide" [11][28]. Financial Performance - The report indicates that the overall retail sales of cosmetics in China reached 229.1 billion yuan in the first half of 2025, with a year-on-year growth of 2.9%, although June saw a decline of 2.3% due to promotional timing [21][24]. - The performance of major companies like Meili Tianyuan is highlighted, with projected revenue of at least 1.45 billion yuan for the first half of 2025, representing a growth of at least 27% [24].

Investment Rating - The report assigns an "Accumulate" rating for the company, indicating a positive outlook for the stock over the next six months [4]. Core Insights - The company has a well-established brand matrix based on skin science and biological science, focusing on the research, design, production, sales, and service of various cosmetics [1][9]. - The main brand, Marubi, has successfully implemented a big product strategy, particularly in eye care, maintaining the top sales position in this category for three consecutive years [2]. - The PL brand, focusing on base makeup, has achieved significant sales milestones, with multiple products exceeding 100 million yuan in annual GMV [3]. Financial Performance - The company is projected to achieve revenues of 2,226 million yuan in 2023, growing to 6,051 million yuan by 2027, with a compound annual growth rate (CAGR) of approximately 24.6% [1][10]. - The net profit attributable to shareholders is expected to rise from 259 million yuan in 2023 to 729 million yuan in 2027, reflecting a strong growth trajectory [1][10]. - The company's gross margin improved to 73.7% in 2024, up 3.01 percentage points year-on-year, driven by optimized product structure and cost control [8]. Brand Strategy - Marubi's core philosophy is centered around "focusing on reducing every fine line," which has solidified its brand identity in eye care and wrinkle reduction [2]. - The PL brand emphasizes user-friendly and high-quality products, reinforcing its market position in the base makeup category [3]. Market Position - Marubi has become a leading brand in the domestic mid-to-high-end skincare market, while PL has established itself as a strong player in the makeup segment [1][3]. - The company aims to leverage global leading technologies to develop high-quality products, guided by a long-term strategy focused on "technology-driven beauty and health" [9].

Investment Rating - The report maintains a positive outlook on the cosmetics and medical beauty industry, indicating a "Buy" recommendation for several companies within the sector [2][14]. Core Insights - The cosmetics and medical beauty sector has shown weaker performance compared to the market, with the Shenwan Beauty Care Index rising by 1.5% from July 4 to July 11, 2025, which is below the market average [3][5]. - The introduction of new products in the regenerative medicine sector, particularly in the "童颜针" (youthful needle) category, is expected to enhance consumer interest and expand the market [2][8]. - The report highlights strong anticipated earnings growth for several key companies in the cosmetics sector for the second quarter of 2025, with notable increases in revenue and net profit for brands like 上美股份 (Shangmei), 丸美股份 (Marubi), and 珀莱雅 (Proya) [9][10][11]. Summary by Sections Industry Performance - The cosmetics and medical beauty sector has underperformed the market, with specific indices showing varied performance, such as the Shenwan Cosmetics Index increasing by 2.6% [3][5]. - The report notes that the demand for cosmetics is recovering, with a 4.1% year-on-year increase in retail sales for the first five months of 2025 [19][20]. Company Performance - 上美股份 (Shangmei) is expected to see a revenue increase of 16% and a net profit increase of 25% in the first half of 2025 [10]. - 丸美股份 (Marubi) anticipates a 22% revenue growth and a 28% increase in net profit for the second quarter of 2025 [10]. - 珀莱雅 (Proya) is projected to achieve a 10% revenue growth and a 15% increase in net profit for the second quarter of 2025 [10]. - 毛戈平 (Mao Geping) expects a significant revenue increase of 38% and a net profit increase of 35% in the first half of 2025 [10]. - 若羽臣 (Ruoyuchen) forecasts a remarkable 70% revenue growth and a 75% increase in net profit for the second quarter of 2025 [10]. Market Trends - The report emphasizes the ongoing trend of domestic brands gaining market share, with national brands occupying five of the top ten positions in the skincare market [32]. - The regenerative medicine sector is expanding, with new products enhancing consumer engagement and market growth potential [2][8]. Investment Recommendations - The report recommends focusing on companies with strong brand matrices and high growth potential, such as 上美股份 (Shangmei), 珀莱雅 (Proya), and 丸美股份 (Marubi) [14]. - It suggests monitoring companies that leverage e-commerce and social media platforms effectively, such as 若羽臣 (Ruoyuchen) and 毛戈平 (Mao Geping) [14].

Core Viewpoint - The establishment of the market position evaluation system by the China Fragrance and Cosmetic Industry Association marks a significant shift in the Chinese cosmetics industry, emphasizing brand building and long-term value over mere sales figures [2][3][4]. Group 1: Market Position Evaluation System - The new market position evaluation system aims to promote brand building and support companies that adhere to long-term value principles, rather than simply ranking based on sales [4][5]. - The evaluation system is based on a comprehensive data collection process, including online and offline retail channels, and involves multiple verification steps to ensure accuracy [8][11]. - The system's key indicators include total retail sales (weighted at 70%) and brand accumulation (weighted at 30%), with a strict one-vote veto policy for brands with significant quality issues [11][12]. Group 2: Industry Insights and Trends - The Chinese cosmetics market has maintained a scale exceeding 1 trillion yuan, with projected market sizes of 1,044.55 billion yuan for 2023 and 1,073.82 billion yuan for 2024 [4]. - The top 50 brands accounted for 21.74% of the total retail sales in 2024, with 22 Chinese brands making the list, reflecting the rapid rise of local brands due to their adaptability to online channels [30][32]. - Despite the progress, Chinese brands still face challenges in achieving quality upgrades, as they primarily occupy the lower segments of the market structure [32][33]. Group 3: Industry Response and Future Directions - The release of the evaluation results has generated significant media attention and industry response, with many executives recognizing the importance of brand value in a changing market landscape [15][17][19]. - Companies are focusing on enhancing their brand value through technological innovation, quality control, and organizational evolution, as emphasized by industry leaders [34][35]. - The association aims to create a systematic approach to promote high-quality development across the entire cosmetics industry, advocating for a shift from a "tack" structure to an "olive" structure, which would support the growth of mid-tier companies [33][37].

Core Insights - The report maintains an "outperform" rating for the retail sector, anticipating that easing international conditions and domestic policy stimulus will positively influence the sector's performance [3][42]. - The overall retail sales in May 2025 reached 4.13 trillion, growing by 6.4% year-on-year, with goods retail sales increasing by 6.5% [11][14]. Beauty and Personal Care - In May 2025, the cosmetics retail sales grew by 4.4%, with high online penetration leading to diminishing promotional effects. However, leading domestic brands are expected to outperform the market due to the trend of domestic product substitution [11][12]. - The competitive landscape is intensifying, with rising sales expense ratios expected to pressure profit margins for some brands, although top players with strong product innovation may still achieve robust growth [11][12]. Gold and Jewelry - The gold and jewelry sector saw a significant year-on-year growth of 21.8% in May 2025, benefiting from a low base effect from the previous year. Products that appeal to younger consumers are expected to drive higher growth rates [11][12]. Supermarkets and Department Stores - From January to May 2025, department store sales slightly increased by 1.3%, while supermarket sales grew by 5.7%. Companies that adapt to the current value-for-money consumption trend through supply chain upgrades are expected to perform better [12][14]. Cross-Border E-commerce - The second quarter is expected to face short-term performance pressures due to external environmental challenges. However, leading platform companies are anticipated to demonstrate strong resilience in the medium to long term due to flexible tariff responses and solid product capabilities [12][14]. Investment Recommendations - The report recommends several companies across different sectors, including: - Beauty and Personal Care: Recommended companies include 毛戈平, 丸美生物, and 登康口腔, which are expected to benefit from domestic product substitution and channel optimization [3][42]. - Gold and Jewelry: Companies like 老铺黄金 and 潮宏基 are highlighted for their potential to achieve accelerated growth due to favorable market conditions [3][42]. - Cross-Border E-commerce: Recommended companies include 小商品城 and 安克创新, which are positioned to capitalize on improving trade conditions [3][42]. - Retail: Companies such as 名创优品 and 重庆百货 are suggested for their low valuation and potential for improvement [3][42].

Core Viewpoint - Marubi has established itself as a leading brand in the eye care segment, achieving significant sales milestones and cultural relevance through its annual "Eye Cream Festival" and collaborations with artists, thereby redefining the standards for domestic eye care products [6][19][28]. Group 1: Brand Recognition and Achievements - Marubi was awarded the title of "First Brand in Domestic Eye Care" by the China Fragrance and Cosmetic Industry Association, highlighting its market leadership and brand strength [16][18]. - The brand has maintained the highest sales in the eye care category for three consecutive years, with its flagship product, the small red pen eye cream, achieving sales of 5 billion [18][19]. - In 2024, Marubi's GMV exceeded 900 million, with an impressive growth rate of 83.9%, further solidifying its position as the leading domestic eye care brand [18]. Group 2: Marketing and Cultural Integration - The 12th "Eye Cream Festival" featured a collaboration with contemporary artist Song Santu, emphasizing the integration of art and culture into the brand's marketing strategy [7][10]. - Marubi's marketing approach has evolved from emotional marketing to emotional engagement, creating a deeper connection with consumers through artistic collaborations [12][14]. - The festival has transformed from a promotional event into a cultural ceremony, enhancing brand identity and consumer engagement [27][28]. Group 3: Product Development and Innovation - Marubi has focused on continuous product innovation, launching multiple iterations of its small red pen eye cream, with the latest version featuring a 25% custom high-concentration peptide formula [22][24]. - The brand has developed a comprehensive product matrix, including key products like the small purple eye cream and butterfly eye mask, to enhance its online presence and sales performance [24]. - Marubi's research and development capabilities have evolved into a fourth-generation system, integrating advanced technologies to ensure product efficacy and safety [27]. Group 4: Strategic Positioning and Market Insights - Marubi's strategy emphasizes systematic capabilities, combining product development, marketing, and consumer trust to create a robust competitive advantage in the eye care market [26][28]. - The brand's long-term commitment to quality and innovation has allowed it to build a strong reputation and consumer loyalty in a highly competitive landscape [19][28]. - Marubi's success illustrates that a brand can thrive in the beauty industry without relying on anxiety-driven narratives, focusing instead on product quality and cultural depth [28][29].

Market Performance - The market experienced an upward trend last week, with the CSI Xinhua National Brand Index rising by 1.39% to 1649.96 points [1][2] - The Shanghai Composite Index increased by 1.40%, the Shenzhen Component Index by 1.25%, the ChiNext Index by 1.50%, and the CSI 300 Index by 1.54% [2] Strong Stock Performances - Notable strong performers included Anji Technology, which rose by 7.98%, and WuXi AppTec, which increased by 7.58% [2] - Other significant gainers included Yiling Pharmaceutical, Tiger Med, and AVIC Shenyang Aircraft, all rising over 6% [2] - The overall trend showed many stocks in the index gaining over 1%, indicating broad market strength [2] Year-to-Date Performance - Since the beginning of 2025, notable stock performances include: - Xintai rising by 55.34% - Anji Technology increasing by 45.75% - WuXi AppTec and Marubi both rising over 30% [3] Market Outlook - Analysts from Xing Shi Investment suggest that the market will continue to perform positively due to strong trading sentiment and sector rotation opportunities [4] - The overall risk premium in the A-share market remains at historically low levels, indicating high value [4] - The macroeconomic environment is expected to remain stable, with ongoing domestic policy support and emerging opportunities in sectors like artificial intelligence and new consumption [4][5] Investment Strategy - Wangzheng Asset maintains a strategy focused on "technology blue chips + innovative growth," emphasizing quality of business operations and undervalued stocks in sectors such as internet, electronics, and automotive [5] - The focus is also on high-potential innovative growth sectors as they mature and enter rapid growth phases [5]

Investment Rating - The report maintains a "Positive" outlook on the cosmetics and medical beauty industry [2]. Core Insights - The cosmetics and medical beauty sector underperformed the market during the week of June 27 to July 4, 2025, with the Shenwan Beauty Care Index declining by 0.6% and the Shenwan Cosmetics Index down by 1.5% [3][4]. - Domestic brands such as Maogeping and others showed significant growth, with some achieving over 50% growth in June, which is expected to positively impact Q2 performance [3][9]. - The report highlights a strong performance from leading domestic brands during the 618 shopping festival, with a notable increase in sales momentum post-event [9][10]. Summary by Sections Industry Performance - The Shenwan Beauty Care Index decreased by 0.6%, while the Shenwan Cosmetics Index fell by 1.5%, indicating weaker performance compared to the Shenwan A Index [4]. - The personal care products index saw a slight increase of 0.7%, but still lagged behind the Shenwan A Index by 0.4% [4]. Key Company Performance - Expected performance for major companies in Q2 includes: - Upbeauty: Revenue and net profit expected to grow by 16% and 25% respectively [11]. - Marubi: Anticipated revenue and net profit growth of 22% and 28% [11]. - Proya: Projected revenue and net profit growth of 10% and 15% [11]. - Maogeping: Expected revenue and net profit growth of 38% and 35% [11]. - Ruifeng: Anticipated growth of 70% and 75% in revenue and net profit respectively [11]. - Juzhibio: Expected growth of 25% and 20% in revenue and net profit [11]. Market Trends - The report notes a robust recovery in consumer demand, with a 4.1% year-on-year increase in retail sales for cosmetics in the first five months of 2025 [20]. - The domestic market is seeing a shift with local brands gaining market share, as evidenced by the performance of brands like Proya and Maogeping during major shopping events [34]. Investment Recommendations - Recommended stocks include: - Upbeauty, Proya, and Marubi for their comprehensive brand matrices and growth potential [15]. - Maogeping and Juzhibio for their strong positioning in niche markets [15]. - Attention is advised for Shanghai Jahwa, Betaini, and Huaxi Biological for potential growth [15]. E-commerce Insights - Data from Douyin indicates significant growth for domestic brands, with Han Shu achieving a GMV of 7.2 billion yuan, reflecting a 53% year-on-year increase [16]. - The overall GMV for domestic brands in June reached over 50% growth, indicating a strong market presence [9][16].

Investment Rating - The report rates the cosmetics and medical beauty industry as "Positive" [2][3] Core Viewpoints - The cosmetics retail sales growth for January to May 2025 is 4.1%, an increase of 2 percentage points compared to the same period last year, indicating a steady recovery in demand [3] - The performance of leading brands remains strong, with double-digit growth, supported by the theme of self-care in new consumption trends, leading to a positive outlook for the first half of 2025 [3] - The 618 shopping festival saw strong performances from domestic brands, with notable rankings on platforms like Tmall and Douyin [3] Summary by Sections Cosmetics Industry Outlook - The report anticipates significant revenue and net profit growth for major companies in Q2 and H1 2025, with specific forecasts: - Up Beauty Co. is expected to see a revenue increase of 16% and a net profit increase of 25% [3] - Marubi is projected to grow revenue by 22% and net profit by 28% in Q2 2025 [3] - Proya is expected to achieve a revenue growth of 10% and net profit growth of 15% in Q2 2025 [3] Key Companies Performance - Notable companies and their expected performance include: - Mao Geping is projected to have a revenue increase of 38% and net profit increase of 35% in H1 2025 [3] - Ruibin is expected to see a revenue increase of 15% and net profit increase of 15% in Q2 2025 [3] - Huaxi Biological is expected to maintain stable performance with a 0% revenue growth and a 10% net profit increase in Q2 2025 [3] Investment Recommendations - The report recommends focusing on companies with strong brand matrices and comprehensive product layouts, such as Up Beauty Co., Marubi, and Proya, which are expected to benefit from the live e-commerce traffic [3] - It also highlights the importance of niche market players like Ruibin and Mao Geping, who are positioned to capitalize on the rise of personal care and domestic beauty trends [3] - For the medical beauty sector, the report suggests focusing on companies with high R&D barriers and strong profitability, recommending companies like Aimeike and Langzi [3] E-commerce and Other Segments - The report suggests monitoring e-commerce companies like Ruibin, which is expected to see significant growth in revenue and net profit [3] - In the maternal and infant sector, Kid King is projected to exceed market expectations with a revenue increase of 10% and a net profit increase of 70% in Q2 2025 [3]